Get started
Author

Shumyla Saeed-Khawaja

Observed names: S. Saeed-Khawaja, S. Saeed‐Khawaja, Saeed-Khawaja, Shumyla, Shumyla Saeed‐Khawaja
Observed institutions: Johnson & Johnson (United States), Justus-Liebig-Universität Gießen, Leiden University Medical Center, Takeda (United States), Janssen Research & Development (United States), University of Birmingham, The University of Texas at Austin
ORCID: 0009-0002-3755-1925
Observed ORCID: 0009-0002-3755-1925
OpenAlex ID: A5092986985
Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and Newborn
2024 · Kenneth J. Moise, Leona E. Ling, et al. · New England Journal of Medicine · 113
Design of a Phase 3, Global, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn
2024 · Yosuke Komatsu, E.J.T. Joanne Verweij, et al. · American Journal of Perinatology · 29
Infant Immunity after Maternal Nipocalimab in Severe Hemolytic Disease of the Fetus and Newborn
2026 · Derek P. de Winter, Kenneth J. Moise, et al. · NEJM Evidence · 5
Efficacy, Safety, Tolerability, and Serum IgG Trough Levels of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in US Pediatric Patients with Primary Immunodeficiency Diseases
2025 · Niraj C. Patel, Jolan E. Walter, et al. · Journal of Clinical Immunology · 3
232 Nipocalimab pharmacokinetic/pharmacodynamic and exposure-response modeling in pregnancies at risk for early-onset severe (EOS) HDFN
2024 · Jie Zhou, Jocelyn H. Leu, et al. · American Journal of Obstetrics and Gynecology · 3
PDF
Plain Language Summary of Publication: Design of the Phase 3 AZALEA Trial of Nipocalimab in Severe Hemolytic Disease of the Fetus and Newborn
2025 · Yosuke Komatsu, Victor Olusajo, et al. · American Journal of Perinatology · 2
fSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety study
2024 · Peter Čižnár, Marion Roderick, et al. · Allergy Asthma and Clinical Immunology · 2
PDF
503 Fetal and neonatal drug exposure following nipocalimab treatment in pregnant women at risk of EOS-HDFN
2024 · Edwin Lam, Jocelyn H. Leu, et al. · American Journal of Obstetrics and Gynecology · 2
PDF
Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and Newborn
2025 · K.J. Moise, L.E. Ling, et al. · Obstetrical & Gynecological Survey · 1
Paediatric outcomes after maternal nipocalimab for haemolytic disease of the fetus and newborn: an open-label, single-arm study
2026 · Derek P de Winter, Kenneth J Moise, et al. · Archives of Disease in Childhood Fetal & Neonatal
PDF
Nipocalimab Phase 3 Dose Selection for Severe Hemolytic Disease of the Fetus and Newborn
2026 · Jie Zhou, Yuan Xiong, et al. · The Journal of Clinical Pharmacology
Characterization of the clinical course of early‐onset severe hemolytic disease of the fetus and newborn
2026 · Dick Oepkes, Kenneth J. Moise, et al. · Pregnancy
Nipocalimab pharmacokinetic/pharmacodynamic and exposure-response modeling in pregnancies at risk for early-onset severe (EOS) HDFN
2024 · Jessie Zhou, Jocelyn Leu, et al.
OC07.03: Nipocalimab pharmacodynamics in a phase 2 study in pregnancies at risk of early‐onset severe hemolytic disease of the fetus and newborn
2023 · L. E. Ling, J. H. Leu, et al. · Ultrasound in Obstetrics and Gynecology
Works count: 20
Citation count: 160
H-index: 3
I10-index: 2
Year
Topic
Type